arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

EyePoint, Inc.

EYPT
$3.73 ▼ -0.35 (-8.48%) at close
Industrials ·Laboratory Analytical Instruments ·USLaboratory Analytical Instruments
66 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Bearish
auto_awesome

Analytical Summary

EyePoint, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —
Dividend Yield —
Revenue Growth -90.5% ↗
Op. Margin None
ROIC -58.5% ↘
FCF / Share None
Trailing P/E —
Price / Book 1.9x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

66-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$507.00K
↓ -90.5% —
Net Income Profit after all expenses
$-94.47M
↓ -59.0% —
Operating Margin Operating profit as % of sales
-199.7%
↑ +48.8% —
FCF / Share Free cash flow per share
$-0.77
↓ -65.7% —
Long-Term Debt Long-term obligations
$0.00
— —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
12
Cash Quality ↑
68

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 18 years · 66 quarters